These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38055246)

  • 1. Overcoming Resistance in Chronic Lymphocytic Leukemia-Maybe Less Is More?
    Al-Sawaf O; Davids MS
    Clin Cancer Res; 2024 Feb; 30(3):471-473. PubMed ID: 38055246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.
    Lucas F; Larkin K; Gregory CT; Orwick S; Doong TJ; Lozanski A; Lozanski G; Misra S; Ngankeu A; Ozer HG; Sampath D; Thangavadivel S; Yilmaz SA; Rogers KA; Byrd JC; Woyach JA; Blachly JS
    Blood; 2020 Jun; 135(24):2192-2195. PubMed ID: 32232486
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
    Kanagal-Shamanna R; Jain P; Patel KP; Routbort M; Bueso-Ramos C; Alhalouli T; Khoury JD; Luthra R; Ferrajoli A; Keating M; Jain N; Burger J; Estrov Z; Wierda W; Kantarjian HM; Medeiros LJ
    Cancer; 2019 Feb; 125(4):559-574. PubMed ID: 30508305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?
    Lampson BL; Brown JR
    Expert Rev Hematol; 2018 Mar; 11(3):185-194. PubMed ID: 29381098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.
    Wiśniewski K; Puła B
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.
    Liu TM; Woyach JA; Zhong Y; Lozanski A; Lozanski G; Dong S; Strattan E; Lehman A; Zhang X; Jones JA; Flynn J; Andritsos LA; Maddocks K; Jaglowski SM; Blum KA; Byrd JC; Dubovsky JA; Johnson AJ
    Blood; 2015 Jul; 126(1):61-8. PubMed ID: 25972157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia.
    Raghunathan V; Fan G; Kittai AS; Okada C; Danilov AV; Spurgeon SE
    Eur J Haematol; 2021 Feb; 106(2):294-297. PubMed ID: 33089525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.
    Bonfiglio S; Sutton LA; Ljungström V; Capasso A; Pandzic T; Weström S; Foroughi-Asl H; Skaftason A; Gellerbring A; Lyander A; Gandini F; Gaidano G; Trentin L; Bonello L; Reda G; Bödör C; Stavroyianni N; Tam CS; Marasca R; Forconi F; Panayiotidis P; Ringshausen I; Jaksic O; Frustaci AM; Iyengar S; Coscia M; Mulligan SP; Ysebaert L; Strugov V; Pavlovsky C; Walewska R; Österborg A; Cortese D; Ranghetti P; Baliakas P; Stamatopoulos K; Scarfò L; Rosenquist R; Ghia P
    Blood Adv; 2023 Jun; 7(12):2794-2806. PubMed ID: 36696464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.
    Jones D; Woyach JA; Zhao W; Caruthers S; Tu H; Coleman J; Byrd JC; Johnson AJ; Lozanski G
    Leukemia; 2017 Jul; 31(7):1645-1647. PubMed ID: 28366935
    [No Abstract]   [Full Text] [Related]  

  • 11. Noncatalytic Bruton's tyrosine kinase activates PLCγ
    Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
    J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of resistance to BTK inhibitors in patients with chronic lymphocytic leukemia.
    Woyach JA
    Clin Adv Hematol Oncol; 2021 Jul; 19(7):436-438. PubMed ID: 34236341
    [No Abstract]   [Full Text] [Related]  

  • 13. Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies.
    Lama TG; Kyung D; O'Brien S
    Expert Rev Hematol; 2020 Aug; 13(8):871-883. PubMed ID: 32673127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL).
    Chirino A; Montoya S; Safronenka A; Taylor J
    Genes (Basel); 2023 Dec; 14(12):. PubMed ID: 38137005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia.
    Wong RL; Choi MY; Wang HY; Kipps TJ
    Leukemia; 2024 Aug; 38(8):1818-1821. PubMed ID: 39048721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Means and Challenges in the Targeting of BTK.
    Nawaratne V; Sondhi AK; Abdel-Wahab O; Taylor J
    Clin Cancer Res; 2024 Jun; 30(11):2333-2341. PubMed ID: 38578606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of
    Quinquenel A; Fornecker LM; Letestu R; Ysebaert L; Fleury C; Lazarian G; Dilhuydy MS; Nollet D; Guieze R; Feugier P; Roos-Weil D; Willems L; Michallet AS; Delmer A; Hormigos K; Levy V; Cymbalista F; Baran-Marszak F;
    Blood; 2019 Aug; 134(7):641-644. PubMed ID: 31243043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibrutinib treatment of CLL: the cancer fights back.
    Young RM; Staudt LM
    Cancer Cell; 2014 Jul; 26(1):11-3. PubMed ID: 25026208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.
    Jain N; Croner LJ; Allan JN; Siddiqi T; Tedeschi A; Badoux XC; Eckert K; Cheung LWK; Mukherjee A; Dean JP; Szafer-Glusman E; Seymour JF
    Clin Cancer Res; 2024 Feb; 30(3):498-505. PubMed ID: 37955424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.
    Sharma S; Galanina N; Guo A; Lee J; Kadri S; Van Slambrouck C; Long B; Wang W; Ming M; Furtado LV; Segal JP; Stock W; Venkataraman G; Tang WJ; Lu P; Wang YL
    Oncotarget; 2016 Oct; 7(42):68833-68841. PubMed ID: 27626698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.